BioMarker Strategies Announces United States Patent For Pathmap Functional Signaling Profile Technology
Published: Sep 26, 2017
“Compositions and Methods for Prediction of Drug Sensitivity, Resistance, and Disease Progression” (#US9766249)
ROCKVILLE, Md.--(BUSINESS WIRE)--BioMarker Strategies, LLC, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering the Company’s PathMAP® Functional Signaling Profile technology.
“PathMAP Functional Signaling Profiles are made possible by our proprietary SnapPath Cancer Diagnostics System, which was developed specifically to enable predictive tests to guide targeted drug development and treatment selection for patients with solid tumor cancers,” said Jerry Parrott, President and CEO, BioMarker Strategies. “PathMAP Profiles are highly predictive of individual solid tumor responses to targeted therapies and combinations because they are based on the dynamic, predictive signaling information available only from live cells.”
A patent covering BioMarker Strategies’ SnapPath® Cancer Diagnostics System technology was granted by the USPTO in 2015 (#US9121801: “Improved Methods and Devices for Cellular Analysis”).
“Our Company was founded to address the reality that available biomarker tests for solid tumors primarily rely on dead, fixed tissue samples,” Mr. Parrott said. “Tests based on such static samples can identify mutations and suggest general therapeutic approach, but are not generally useful in identifying or understanding mechanisms of acquired resistance, and do not accurately and dependably predict individual tumor response to treatment.”
The SnapPath and PathMAP technologies are ideally suited to assess response to targeted drugs in development for the treatment of solid tumor cancers. The BioMarker Strategies business model is focused on using the Company’s proprietary ex vivo technology to provide research services to companies developing targeted drugs and combinations for the treatment of patients with solid tumor cancers.
Patents covering the SnapPath Cancer Diagnostics System have been granted in the United States, Europe, Australia, Hong Kong, Japan and Korea. A patent has also been officially allowed and is proceeding to grant in Canada.
Patents covering the PathMAP Functional Signaling Profile technology have now been granted in the United States, Europe, Australia, Japan and Singapore, and patent applications are pending elsewhere.
About BioMarker Strategies
BioMarker Strategies has developed the SnapPath Cancer Diagnostics System. SnapPath is an automated and highly customizable fluidics-based system consisting of a compact bench-top instrument and a single-use cartridge for required consumables and reagents. The SnapPath system generates purified populations of live solid tumor cells from fresh biopsies or other fresh unfixed tissue samples such as xenografts or tumorgrafts, and keeps them alive on the instrument to enable generation of the highly predictive biomarker tests the Company has named PathMAP Functional Signaling Profiles.
PathMAP Functional Signaling Profiles are useful in identifying and understanding mechanisms of acquired resistance, and are highly predictive of individual tumor response to targeted therapies and combinations. BioMarker Strategies also believes that PathMAP Functional Signaling Profiles will prove highly predictive of individual tumor response to immunotherapeutic approaches and combinations.
The capabilities of SnapPath and the Functional Signaling Profiles it enables are available for use in preclinical studies in tumorgraft and other model systems, and in early clinical studies to assess pharmacodynamic changes in the solid tumors of individual patients. For more information about BioMarker Strategies, please see www.biomarkerstrategies.com.
The information in this press release includes our projections and other forward-looking statements regarding future events. In some cases, forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “projects,” “estimates,” “predicts,” “potential,” “continue”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is projected here.
BioMarker Strategies, LLC
Jerry Parrott, President & CEO